Investing.com - ARS Pharmaceuticals (NASDAQ: SPRY) reported third quarter EPS of $-0.20, $0.06 worse than the analyst estimate of $-0.14. Revenue for the quarter came in at $2.07M versus the consensus estimate of $500K.
ARS Pharmaceuticals's stock price closed at $16.61. It is up 24.61% in the last 3 months and up 292.67% in the last 12 months.
ARS Pharmaceuticals saw 1 positive EPS revisions and 1 negative EPS revisions in the last 90 days. See ARS Pharmaceuticals's stock price’s past reactions to earnings here.
According to InvestingPro, ARS Pharmaceuticals's Financial Health score is "good performance".
Check out ARS Pharmaceuticals's recent earnings performance, and ARS Pharmaceuticals's financials here.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar